About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
B
Early Enzalutamide, Apalutamide, or Abiraterone Are the New Standard Treatment of Early Asymptomatic mCRPC / Rapidly Progression nmCRPC
By
Global Congress on Prostate Cancer - PROSCA 2019
FEATURING
Bertrand Tombal
By
Global Congress on Prostate Cancer - PROSCA 2019
FEATURING
Bertrand Tombal
762 views
January 7, 2020
0 Comments
Login to view comments.
Click here to Login
Featured Video
20:25
Exelixis
Primary Analysis and Follow-up Data of a Combination Therapy in 1L a…
Feat.
S. Ratnam
Featured Video
19:47
Janssen Oncology
All Things PSA
Feat.
J. Hamilton,
M. Fabrizio,
M. Taha
Related Content
AUTOPLAY
ON
11:56
Ana Aparicio
Aggressive Variant Prostate Cancer: Definition, Diagnosis, Treatment…
14:16
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Summary: "Important Prostate Cancer Take-Home Mes…
Feat.
E. Efstathiou
09:14
Robert Dreicer
AUA Advanced Prostate Cancer Guidelines: 2023 Update
16:05
Insights from 2024 ASCO® GU Annual Meeting
Recent GU Developments and Their Clinical Implications
Feat.
T. Powles,
B. Rini
27:04
Fengting Yan
Cancer Screening Molecular Tools
05:18
Insights from 2023 ASCO® Annual Meeting
ASCO® 2023 Insights: "PSMAddition - A Phase 3 Trial to Compare …
Feat.
S. Tagawa
08:05
Total Health
Prostate Cancer Updates From ASCO® 2023
Feat.
T. Zhang
11:39
Oncology Data Advisor
Recent Prostate Cancer Updates
Feat.
U. Vaishampayan
21:17
Manish Kohli
Time to Castrate Resistance in mCSPC Using Standard of Care Intensif…
19:07
Stanford Medicine
Stanford Medicine Advances in Imaging to Improve Prostate Cancer Dia…
Feat.
G. Sonn
09:45
Northwestern Medicine Oncology and Hematology
Differences Between Urologists and Medical Oncologists in the Manage…
Feat.
W. Catalona
25:33
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute Prostate Cancer Updates From ASCO GU 20…
Feat.
J. Berchuck,
A. Choudhury
12:39
ASCO GU 2023 Conference Coverage
Efficacy and Safety of Darolutamide in Combination With ADT and Doce…
Feat.
C. Sternberg
17:50
AdventHealth
Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…
Feat.
G. Sonpavde
10:13
Judd Moul
Treatment Intensification in Advanced Prostate Cancer
10:12
Insights from 2023 ESMO Annual Meeting
ESMO 2023 Insights: "Phase 3 Randomized EMBARK Study - Enzaluta…
Feat.
S. Freedland
14:51
Insights from 2024 ASCO® GU Annual Meeting
ASCO® GU 2024 Summary: "Tailoring Prostate Cancer Care - EMBARK…
Feat.
S. Freedland
34:43
OncoAlert
Year in Review: Therapeutic Advances in Prostate Cancer
Feat.
N. Agarwal
11:12
E. David Crawford
Phase 3 ARASENS Trial: Overall Safety & Incidences of Adverse Ev…
42:54
Houston Methodist Hospital
30 Years Perspective on Advanced Prostate Cancer: Using Biology &…
Feat.
M. Hussain
